Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Rev Vaccines. 2011 Aug;10(8):1117-20. doi: 10.1586/erv.11.97.

Clinical evaluation of a soluble trimeric HIV-1 envelope glycoprotein vaccine.

Author information

  • 1Laboratory of Experimental Virology, Department of Medical Microbiology, Academic Medical Center of the University of Amsterdam, Amsterdam The Netherlands. r.w.sanders@amc.uva.nl

Abstract

Designing an HIV-1 envelope glycoprotein (Env) that can induce broadly neutralizing antibodies in humans remains one of the great challenges in biomedical research. Monomeric gp120 has repeatedly failed to induce cross-neutralizing antibodies in clinical trials. Spearman et al. vaccinated uninfected volunteers with a trimeric gp140 protein. They found that the vaccine was safe and induced neutralizing antibody responses against the homologous virus, but not cross-neutralizing responses. The results reinforce the notion that our Env vaccine design needs to improve.

PMID:
21854306
[PubMed]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk